Skip to main content

Table 4 Adverse events occurring in ≥ 3% of patients in any treatment group

From: Comparison of rosuvastatin and atorvastatin for lipid lowering in patients with type 2 diabetes mellitus: results from the URANUS study

 

Number (%) of patients with adverse event

Adverse event

Rosuvastatin (n = 233)

Atorvastatin (n = 236)

Nasopharyngitis

23 (9.9)

19 (8.1)

Myalgia

13 (5.6)

7 (3.0)

Inadequately controlled diabetes mellitus

14 (6.0)

11 (4.6)

Constipation

9 (3.9)

6 (2.5)

Headache

6 (2.6)

7 (3.0)

Urinary tract infection

9 (3.9)

2 (0.9)

Arthralgia

1 (0.4)

9 (3.8)